<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000703</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 008</org_study_id>
    <secondary_id>10984</secondary_id>
    <nct_id>NCT00000703</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members</brief_title>
  <official_title>Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine&#xD;
      (AZT) treatment for patients with peripheral lymphoma.&#xD;
&#xD;
      Other chemotherapies have been tried in patients with AIDS related lymphomas, but the results&#xD;
      have not been satisfactory. This study will show whether the combination of chemotherapy,&#xD;
      radiation, and AZT is more effective and less toxic than previously used treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other chemotherapies have been tried in patients with AIDS related lymphomas, but the results&#xD;
      have not been satisfactory. This study will show whether the combination of chemotherapy,&#xD;
      radiation, and AZT is more effective and less toxic than previously used treatments.&#xD;
&#xD;
      All patients will receive combination chemotherapy and AZT. The combination chemotherapy will&#xD;
      be repeated every 3 to 4 weeks for a maximum total of 6 cycles. Each cycle will consist of&#xD;
      doxorubicin, bleomycin, cyclophosphamide, and vincristine on day 1, dexamethasone on days&#xD;
      1-5, and methotrexate on day 15. Patients with meningeal or bone marrow disease will receive&#xD;
      radiation and intrathecal cytarabine (ARA-C) while those without will receive ARA-C without&#xD;
      radiation. Patients with documented lymphomas in the central nervous system at initial workup&#xD;
      will start radiation as soon as possible and intrathecal ARA-C (t.i.w. until cerebrospinal&#xD;
      fluid is clear then every month for 1 year); patients with normal lumbar puncture, brain&#xD;
      scan, and bone marrow at first diagnosis will begin radiation on day 1 of cycle 3 of&#xD;
      chemotherapy. Lumbar punctures for evaluation will be done four times during the first cycle,&#xD;
      on days 1, 8, 21, and 28. AZT will be administered every 4 hours, 7 days a week, beginning at&#xD;
      the completion of combined chemotherapy, once the patient has achieved a complete remission&#xD;
      of the lymphoma, and continuing for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 1990</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Ibuprofen.&#xD;
&#xD;
          -  Standard antiemetic agents.&#xD;
&#xD;
          -  Ganciclovir therapy for sight- or life-threatening Cytomegalovirus infection.&#xD;
&#xD;
          -  Zidovudine and methotrexate may be resumed during ganciclovir maintenance phase.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        The following patients will be excluded from the study:&#xD;
&#xD;
          -  Patients with recurrent infection that may interfere with the planned protocol.&#xD;
&#xD;
          -  Patients with a second active tumor other than nonmelanomatous skin cancer or Kaposi's&#xD;
             sarcoma.&#xD;
&#xD;
          -  Patients with stage IE primary central nervous system lymphoma.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Aspirin.&#xD;
&#xD;
          -  Acetaminophen.&#xD;
&#xD;
          -  Nonsteroidal anti-inflammatory drugs, except ibuprofen.&#xD;
&#xD;
          -  Chemotherapy for infection associated with neutropenia.&#xD;
&#xD;
          -  Zidovudine (AZT) for infection associated with neutropenia.&#xD;
&#xD;
          -  Investigational therapies, except ganciclovir therapy for sight- or life-threatening&#xD;
             cytomegalovirus infection.&#xD;
&#xD;
          -  AZT and methotrexate will be suspended during induction therapy with ganciclovir.&#xD;
&#xD;
        The following patients will be excluded from the study:&#xD;
&#xD;
          -  Patients with recurrent infection that may interfere with the planned protocol.&#xD;
&#xD;
          -  Patients with a second active tumor other than nonmelanomatous skin cancer or Kaposi's&#xD;
             sarcoma.&#xD;
&#xD;
          -  Patients with stage IE primary central nervous system lymphoma.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
          -  Antiretroviral therapy prior to diagnosis of lymphoma.&#xD;
&#xD;
        Patients must demonstrate the following clinical and laboratory findings:&#xD;
&#xD;
          -  Any stage of the disease, including stage I.&#xD;
&#xD;
          -  Newly diagnosed, previously untreated high-grade lymphoma.&#xD;
&#xD;
          -  Presence of measurable tumor parameter(s).&#xD;
&#xD;
          -  Adequate hepatic, renal, and bone marrow function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Levine A</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charity Hosp / Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State Univ Med Ctr / Tulane Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Massachusetts Med Ctr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S Hershey Med Ctr</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>170330850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993 Oct 7;329(15):1065-72. doi: 10.1056/NEJM199310073291502.</citation>
    <PMID>7690462</PMID>
  </reference>
  <reference>
    <citation>Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C, Bennett JM, Rarick MU, Walsh C, Kahn J, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA. 1991 Jul 3;266(1):84-8.</citation>
    <PMID>1710673</PMID>
  </reference>
  <reference>
    <citation>ICDB/89653727. Levine AM, et al. Low dose chemotherapy with CNS prophylaxis and zidovudine (AZT) maintenance for aids-related lymphoma: preliminary results of a multi-institutional study. Proc Annu Meet Am Soc Clin Oncol. 1989 8:A18</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vincristine</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antineoplastic Agents, Combined</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Bleomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

